Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Ultimovacs

Biotech & Life Sciences · Oslo, Norway · Founded 2011 · IPO 2019 Thoroughbred

A pharmaceutical company developing novel immunotherapies against cancer

Valuation
$35M
Market cap · 2026

Investors

1 investor on Ultimovacs's cap table

Sourced from Dealroom's funding history.

Series B+ 1 investor entered at this stage
Uppsala University

Ownership

Who owns Ultimovacs

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

18.9% GJELSTEN HOLDING AS

Some investors are hidden on this public profile. “Other / undisclosed” is the 52.5% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Ultimovacs has talent and traffic

Workforce by country
2 countries with
team presence
🇳🇴 Norway90.1%
🇸🇪 Sweden17%
2 countries shown
Web traffic by country
330 monthly visits
across markets
🇺🇸 United States60.6%
🇬🇧 United Kingdom30.3%
Top 2 markets shown

Talent graph

The shape of Ultimovacs's talent

Dealroom maps Ultimovacs's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

25 standout operatorsDealroom-flagged across the org
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Ultimovacs's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Ultimovacs

An AI-synthesized read of the highest-engagement posts about Ultimovacs on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ultimovacs on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.